Adalimumab for sight-threatening uveitis in Behçet's disease.
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. Case note review. Main outcome measure was recurrence of uveitis. All patients remained free of recurrence with stable visual acuities. Adalimumab appears to maintain disease remission in Behçet's disease.